Catalent, Inc. (NYSE:CTLT) Shares Bought by Readystate Asset Management LP

Readystate Asset Management LP lifted its position in Catalent, Inc. (NYSE:CTLT) by 52.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,223 shares of the company’s stock after acquiring an additional 33,558 shares during the period. Readystate Asset Management LP owned 0.05% of Catalent worth $4,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CTLT. Gladius Capital Management LP purchased a new stake in shares of Catalent in the 3rd quarter valued at $28,000. KB Financial Partners LLC acquired a new stake in Catalent in the 1st quarter valued at about $30,000. Exchange Traded Concepts LLC acquired a new stake in Catalent in the 3rd quarter valued at about $31,000. GAMMA Investing LLC acquired a new stake in Catalent in the 4th quarter valued at about $33,000. Finally, Cary Street Partners Investment Advisory LLC raised its position in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after purchasing an additional 709 shares in the last quarter.

Analyst Upgrades and Downgrades

CTLT has been the subject of several recent analyst reports. Stephens reissued an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. StockNews.com began coverage on Catalent in a research note on Thursday, April 11th. They set a “sell” rating on the stock. Barclays boosted their price objective on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Finally, UBS Group restated a “neutral” rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $52.46.

Catalent Stock Up 0.3 %

Shares of Catalent stock traded up $0.16 during trading hours on Wednesday, reaching $55.94. 1,942,903 shares of the company’s stock were exchanged, compared to its average volume of 2,613,947. The company has a 50 day moving average of $56.85 and a two-hundred day moving average of $48.11. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $60.20. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The stock has a market cap of $10.11 billion, a P/E ratio of -8.23, a P/E/G ratio of 6.05 and a beta of 1.20.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm’s revenue was down 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 earnings per share. On average, sell-side analysts forecast that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.